NCT00690430 - Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Symptomatic Refractory Resistant Carcinoid Disease

Interventions

DRUG

Pasireotide

Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed

DRUG

Octreotide

Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed

Trial Locations (62)

1200

Novartis Investigative Site, Brussels

5020

Novartis Investigative Site, Salzburg

8036

Novartis Investigative Site, Graz

9000

Novartis Investigative Site, Ghent

9038

Novartis Investigative Site, Tromsø

10029

Mount Sinai School of Medicine Study Coordinator, New York

10043

Novartis Investigative Site, Orbassano

10467

Montefiore Medical Center MMC, The Bronx

12200

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

13385

Novartis Investigative Site, Marseille

15706

Novartis Investigative Site, Santiago de Compostela

20132

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

21079

Novartis Investigative Site, Dijon

27710

Duke University Medical Center Dept. of Duke Cancer Center(2), Durham

33612

H. Lee Moffitt Cancer Center/University of South Florida Dept of H. Lee Moffit, Tampa

34295

Novartis Investigative Site, Montpellier

40138

Novartis Investigative Site, Bologna

41100

Novartis Investigative Site, Modena

67098

Novartis Investigative Site, Strasbourg

69120

Novartis Investigative Site, Heidelberg

69437

Novartis Investigative Site, Lyon

80336

Novartis Investigative Site, München

85258

Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale

85724

University of Arizona / Arizona Cancer Center, Tucson

90048

Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles

91120

Novartis Investigative Site, Jerusalem

92110

Novartis Investigative Site, Clichy

92354

Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda

99438

Novartis Investigative Site, Bad Berka

169610

Novartis Investigative Site, Singapore

Unknown

St. Luke's Hospital and Health Network St. Luke's Cancer Network, Bethlehem

Novartis Investigative Site, London

77030-4009

MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (9), Houston

C1264AAA

Novartis Investigative Site, Buenos Aires

C1426ANZ

Novartis Investigative Site, Buenos Aires

A-1090

Novartis Investigative Site, Vienna

60430-370

Novartis Investigative Site, Fortaleza

T2N 2T9

Novartis Investigative Site, Calgary

B3H 2Y9

Novartis Investigative Site, Halifax

H3A 1A1

Novartis Investigative Site, Montreal

06202

Novartis Investigative Site, Nice

D-55101

Novartis Investigative Site, Mainz

06100

Novartis Investigative Site, Perugia

00168

Novartis Investigative Site, Roma

N-7006

Novartis Investigative Site, Trondheim

80-958

Novartis Investigative Site, Gdansk

44-101

Novartis Investigative Site, Gliwice

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

SE-551 85

Novartis Investigative Site, Jönköping

SE-581 85

Novartis Investigative Site, Linköping

SE-221 85

Novartis Investigative Site, Lund

SE-141 86

Novartis Investigative Site, Stockholm

SE-171 76

Novartis Investigative Site, Stockholm

SE-751 85

Novartis Investigative Site, Uppsala

M20 4BX

Novartis Investigative Site, Withington

S10 2JF

Novartis Investigative Site, Sheffield

RG24 9NA

Novartis Investigative Site, Basingstoke

B15 2TH

Novartis Investigative Site, Birmingham

G12 0YN

Novartis Investigative Site, Glasgow